Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
164.00
+1.00 (0.61%)
At close: Jan 21, 2026
142.96%
Market Cap254.20B
Revenue (ttm)34.99M
Net Income (ttm)-488.25M
Shares Out1.55B
EPS (ttm)-0.32
PE Ration/a
Forward PE68.62
Dividendn/a
Ex-Dividend Daten/a
Volume9,236,149
Average Volume5,956,318
Open163.00
Previous Close163.00
Day's Range156.00 - 165.00
52-Week Range54.10 - 277.00
Beta0.68
RSI57.04
Earnings DateFeb 6, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.

Financial Statements